Trial medication Erenumab by Amgen has successfully passed clinical trials among patients with migraine that doesn’t respond to traditional treatment as reported by Reuters.
Clinical trials were conducted in 246 patients (suffering from between 4 and 14 headache attacks per month) who didn't respond on 2-4 prior therapies.
According to the results of clinical trials, Erenumab has reduced by 50% frequency of attacks in 30% of participants in the trials; in placebo group such improvement was recorded only by 14% of participants.
Erenumab is a monoclonal antibody of calcitonin gene-related peptide receptor (CGRPR). This medication is being developed within the framework of the partnership between Amgen and Novartis. In the case of registration, Amgen gains the right to commercialize Erenumab in USA, Canada and Japan and Novartis retains commercialization rights in the territory of Europe and other countries of the world.

BaDM - We work for you!